Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of NKTR-102 (etirinotecan pegol) in subjects previously enrolled in NKTR-102 studies
2011-002797-23Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Jul 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etirinotecan pegol in Non-hematologic malignancy and Nonhematologic neoplasms, sponsored by Nektar Therapeutics. Primary endpoint: Incidence and duration of toxicities. Started Jul 2011; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
Non-hematologic malignancyNonhematologic neoplasms
Beyond the preview
Go deeper on 2011-002797-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002797-23.